Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
GILD vs. ALNY: Which Stock Is the Better Value Option?
12:41pm, Thursday, 23'rd Jan 2025
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Gilead Sciences (GILD) and Alnylam Pharmaceuticals (ALNY). But which of these two stocks
Why Gilead Sciences (GILD) Outpaced the Stock Market Today
07:05pm, Tuesday, 21'st Jan 2025
The latest trading day saw Gilead Sciences (GILD) settling at $92.96, representing a +1.22% change from its previous close.
Can Gilead Sciences Sustain Its Growth Momentum in 2025?
03:06pm, Monday, 20'th Jan 2025
GILD has performed well in the past six months, with new drug approvals, positive data readouts and strong quarterly results. While the fundamentals look solid, we advise investors to remain on the si
The Zacks Analyst Blog Salesforce, Shell and Gilead Sciences
03:21am, Friday, 17'th Jan 2025
Salesforce, Shell and Gilead Sciences are included in this Analyst Blog.
Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?
10:00am, Thursday, 16'th Jan 2025
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
Gilead Sciences (GILD) Rises Yet Lags Behind Market: Some Facts Worth Knowing
07:01pm, Wednesday, 15'th Jan 2025
In the latest trading session, Gilead Sciences (GILD) closed at $92.38, marking a +1.52% move from the previous day.
Gilead Sciences, US government settle patent case over HIV prevention drugs
03:45pm, Wednesday, 15'th Jan 2025
Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to a Wednesday filing in Delaware federal court.
Final Trade: ANF, GILD
06:32pm, Monday, 13'th Jan 2025
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
06:10pm, Monday, 13'th Jan 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil
Gilead Sciences, Inc. (GILD) JPMorgan Annual Healthcare Conference - (Transcript)
05:09pm, Monday, 13'th Jan 2025
Gilead Sciences, Inc. (NASDAQ:GILD ) JPMorgan Annual Healthcare Conference Call January 13, 2025 2:15 PM ET Company Participants Daniel O'Day - Chairman and Chief Executive Officer Johanna Mercier - C
Gilead CEO on funding for new HIV prevention medicine
11:15am, Monday, 13'th Jan 2025
CNBC's Angelica Peebles and Gilead chairman and CEO Daniel O'Day join ‘Squawk Box' to discuss the company's new HIV prevention medicine, impact of the incoming Trump administration on health care, a
Gilead CEO Daniel O'Day on new HIV prevention medicine: It's going to change the face of HIV
09:01am, Monday, 13'th Jan 2025
CNBC's Angelica Peebles and Gilead chairman and CEO Daniel O'Day join 'Squawk Box' to discuss the company's new HIV prevention medicine, impact of the incoming Trump administration on health care, and
Compugen initiated with bullish view at Oppenheimer, here's why
07:57am, Monday, 13'th Jan 2025
Compugen +0.05 (+3.14%) AstraZeneca +0.44 (+0.66%) Gilead +0.7 (+0.79%)
Gilead, LEO Pharma partner to develop programs for inflammatory diseases
12:40pm, Saturday, 11'th Jan 2025
Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat patients with inflammatory diseases.
FOSTER CITY, Calif. & BALLERUP, Denmark--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and commercializatio
